Literature DB >> 20599795

Cannabinoid Receptor 1 trafficking and the role of the intracellular pool: implications for therapeutics.

Natasha L Grimsey1, E Scott Graham, Mike Dragunow, Michelle Glass.   

Abstract

Cannabinoid Receptor 1 (CB(1)), an abundant G-protein coupled receptor in the CNS, is currently of significant interest as a therapeutic target. Although the cellular control of receptor trafficking is intimately linked with drug effects, CB(1) trafficking is poorly defined in the current literature and conflicting evidence exists as to whether CB(1) should be classified as a recycling, degrading or "dual-fate" receptor. Of particular interest is the widely noted intracellular pool which has been speculated to form part of a constitutive internalization and recycling pathway. This study performs a detailed quantification of CB(1) trafficking in four cell lines, one of which expresses CB(1) endogenously. We demonstrate that, contrary to previous reports, CB(1) does not recycle following constitutive or agonist-induced internalization but instead exhibits a primarily degradative phenotype. Further, our data suggest that the intracellular pool does not contribute to cell surface re-population. These findings have significant implications for the interpretation of CB(1) biochemical studies and the design and application of cannabinoid therapeutics. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20599795     DOI: 10.1016/j.bcp.2010.06.007

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  20 in total

Review 1.  Regulation of G protein-coupled receptor signaling by plasma membrane organization and endocytosis.

Authors:  Zara Y Weinberg; Manojkumar A Puthenveedu
Journal:  Traffic       Date:  2019-01-11       Impact factor: 6.215

2.  Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide.

Authors:  G Cristina Brailoiu; Tudor I Oprea; Pingwei Zhao; Mary E Abood; Eugen Brailoiu
Journal:  J Biol Chem       Date:  2011-06-30       Impact factor: 5.157

3.  Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB1 receptors.

Authors:  Xiao Zhu; David B Finlay; Michelle Glass; Stephen B Duffull
Journal:  Br J Pharmacol       Date:  2019-05-21       Impact factor: 8.739

4.  β-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner.

Authors:  Peter T Nguyen; Cullen L Schmid; Kirsten M Raehal; Dana E Selley; Laura M Bohn; Laura J Sim-Selley
Journal:  Biol Psychiatry       Date:  2012-01-20       Impact factor: 13.382

5.  Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors.

Authors:  William J Redmond; Erin E Cawston; Natasha L Grimsey; Jordyn Stuart; Amelia R Edington; Michelle Glass; Mark Connor
Journal:  Br J Pharmacol       Date:  2015-11-17       Impact factor: 8.739

6.  Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.

Authors:  Kwang H Ahn; Mariam M Mahmoud; Debra A Kendall
Journal:  J Biol Chem       Date:  2012-02-16       Impact factor: 5.157

7.  The Alzheimer's disease-protective CD33 splice variant mediates adaptive loss of function via diversion to an intracellular pool.

Authors:  Shoib S Siddiqui; Stevan A Springer; Andrea Verhagen; Venkatasubramaniam Sundaramurthy; Frederico Alisson-Silva; Weiping Jiang; Pradipta Ghosh; Ajit Varki
Journal:  J Biol Chem       Date:  2017-07-26       Impact factor: 5.157

8.  The Synthetic Cannabinoid WIN55,212-2 Can Disrupt the Golgi Apparatus Independent of Cannabinoid Receptor-1.

Authors:  Joshua Lott; Emily M Jutkiewicz; Manojkumar A Puthenveedu
Journal:  Mol Pharmacol       Date:  2022-03-02       Impact factor: 4.054

9.  Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action.

Authors:  Erin E Cawston; William J Redmond; Courtney M Breen; Natasha L Grimsey; Mark Connor; Michelle Glass
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

10.  High tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II microsatellite stable colorectal cancer.

Authors:  Sofia B Gustafsson; Richard Palmqvist; Maria L Henriksson; Anna M Dahlin; Sofia Edin; Stig O P Jacobsson; Åke Öberg; Christopher J Fowler
Journal:  PLoS One       Date:  2011-08-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.